Jack Ishak

512 total citations
20 papers, 374 citations indexed

About

Jack Ishak is a scholar working on Oncology, Hematology and Economics and Econometrics. According to data from OpenAlex, Jack Ishak has authored 20 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Hematology and 5 papers in Economics and Econometrics. Recurrent topics in Jack Ishak's work include Multiple Myeloma Research and Treatments (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Statistical Methods in Clinical Trials (4 papers). Jack Ishak is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Statistical Methods in Clinical Trials (4 papers). Jack Ishak collaborates with scholars based in United States, United Kingdom and Switzerland. Jack Ishak's co-authors include Irina Proskorovsky, Charalampia Kyriakou, Karin Jordan, Cathy Williams, Faith E. Davies, Philip Lewis, J. Jaime, Krista Payne, Sarah Peters and Yijian Huang and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Jack Ishak

19 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jack Ishak United States 9 151 136 93 85 66 20 374
Sumeet Panjabi United States 14 124 0.8× 180 1.3× 106 1.1× 99 1.2× 205 3.1× 71 565
Sandra Cuéllar United States 13 115 0.8× 45 0.3× 98 1.1× 75 0.9× 25 0.4× 30 462
Saskia de Groot Netherlands 12 114 0.8× 76 0.6× 171 1.8× 97 1.1× 12 0.2× 35 440
Bintu Sherif United States 14 92 0.6× 62 0.5× 43 0.5× 20 0.2× 87 1.3× 37 613
Ashraf Mikhail United Kingdom 13 43 0.3× 444 3.3× 45 0.5× 36 0.4× 32 0.5× 25 746
Vishvas Garg United States 13 52 0.3× 49 0.4× 65 0.7× 27 0.3× 22 0.3× 48 469
Chun‐Lan Chang United States 11 53 0.4× 28 0.2× 49 0.5× 67 0.8× 70 1.1× 27 400
Heather Norman United States 14 32 0.2× 40 0.3× 49 0.5× 96 1.1× 72 1.1× 21 567
Konstantina Skaltsa United States 9 117 0.8× 32 0.2× 35 0.4× 39 0.5× 63 1.0× 23 422
Tunghi May Pini United States 5 347 2.3× 55 0.4× 30 0.3× 122 1.4× 31 0.5× 10 556

Countries citing papers authored by Jack Ishak

Since Specialization
Citations

This map shows the geographic impact of Jack Ishak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Ishak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Ishak more than expected).

Fields of papers citing papers by Jack Ishak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack Ishak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Ishak. The network helps show where Jack Ishak may publish in the future.

Co-authorship network of co-authors of Jack Ishak

This figure shows the co-authorship network connecting the top 25 collaborators of Jack Ishak. A scholar is included among the top collaborators of Jack Ishak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack Ishak. Jack Ishak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boentert, Matthias, Kenneth I. Berger, Jordi Díaz‐Manera, et al.. (2024). Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease. Orphanet Journal of Rare Diseases. 19(1). 14–14. 2 indexed citations
2.
Ishak, Jack, et al.. (2018). Projecting survival with cure mixture models: when are the data mature enough for reliable analysis?. Value in Health. 21. S53–S53. 2 indexed citations
3.
Raal, Frederick J., et al.. (2017). The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. European Journal of Preventive Cardiology. 24(17). 1843–1850. 24 indexed citations
4.
Ishak, Jack, Henry Punzi, Alan H. Gradman, et al.. (2017). Additivity of nebivolol/valsartan single‐pill combinations versus other single‐pill combinations for hypertension. Journal of Clinical Hypertension. 20(1). 143–149. 6 indexed citations
5.
Raymond, Éric, Patricia Niccoli, Daniel Castellano, et al.. (2016). Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.. Journal of Clinical Oncology. 34(4_suppl). 309–309. 8 indexed citations
6.
Vernon, Margaret, Don Robinson, Dylan Trundell, et al.. (2016). Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman’s disease. Current Medical Research and Opinion. 32(7). 1193–1200. 5 indexed citations
7.
8.
9.
Jaime, J., Jörgen Möller, Jonathan Karnon, James E. Stahl, & Jack Ishak. (2015). Discrete Event Simulation for Health Technology Assessment. 32 indexed citations
10.
Benedict, Ágnes, Jack Ishak, Péter Gál, et al.. (2015). THU0207 Comparative Analysis of the Effectiveness of anti-TNF Therapies in Non-Radiographic Axial Spondyloarthritis Using Novel Statistical Techniques. Annals of the Rheumatic Diseases. 74. 270–271. 2 indexed citations
11.
Proskorovsky, Irina, Philip Lewis, Cathy Williams, et al.. (2014). Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health and Quality of Life Outcomes. 12(1). 35–35. 52 indexed citations
12.
13.
Muszbek, N., Noémi Kreif, Adriana Valderrama, et al.. (2012). Modelling survival in hepatocellular carcinoma. Current Medical Research and Opinion. 28(7). 1141–1153. 6 indexed citations
14.
Ishak, Jack, Juan W. Valle, Eric Van Cutsem, et al.. (2011). Overall Survival (OS) Analysis of Sunitinib (SU) after Adjustment for Crossover (CO) in Patients with Pancreatic Neuroendocrine Tumors (NET). Neuroendocrinology. 94. 27–28. 1 indexed citations
15.
Stokes, Michael E., Jack Ishak, Irina Proskorovsky, Libby Black, & Yijian Huang. (2011). Lifetime economic burden of prostate cancer. BMC Health Services Research. 11(1). 349–349. 41 indexed citations
16.
Maclaine, Grant, Denis Getsios, Steve Blume, & Jack Ishak. (2009). P3‐224: Updated cost‐effectiveness projections for donepezil in the treatment of patients with mild‐to‐moderately severe Alzheimer's disease in the UK. Alzheimer s & Dementia. 5(4S_Part_13).
17.
Ishak, Jack, et al.. (2008). Declining Rates of Adverse Events and Dose Modifications with Lenalidomide in Combination with Dexamethasone. Blood. 112(11). 3708–3708. 18 indexed citations
18.
Deniz, Baris, Gareth J. Morgan, Steve Schey, et al.. (2008). Economic Evaluation of Lenalidomide Combined with Dexamethasone for the Treatment of Multiple Myeloma in the UK. Blood. 112(11). 2400–2400. 4 indexed citations
19.
Weintraub, William S., Zefeng Zhang, Elizabeth M. Mahoney, et al.. (2005). Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure. Circulation. 111(9). 1106–1113. 51 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sumeet Panjabi Breakdown of academic impact, for papers by Sandra Cuéllar Breakdown of academic impact, for papers by Saskia de Groot Breakdown of academic impact, for papers by Bintu Sherif Breakdown of academic impact, for papers by Ashraf Mikhail Breakdown of academic impact, for papers by Vishvas Garg Breakdown of academic impact, for papers by Chun‐Lan Chang Breakdown of academic impact, for papers by Heather Norman Breakdown of academic impact, for papers by Konstantina Skaltsa Breakdown of academic impact, for papers by Tunghi May Pini
Rankless by CCL
2026